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ABSTRACT 
 
Objective:  
This study examines the cost effectiveness of the OPTI-SCRIPT intervention on potentially 
inappropriate prescribing in primary care. 
 
Methods:  
Economic evaluation, employing incremental cost effectiveness and cost utility analyses, 
conducted alongside a cluster randomised controlled trial of 21 general practices and 196 
patients, to compare a multifaceted intervention to usual practice in primary care in Ireland. 
Potentially inappropriate prescriptions (PIPs) were determined by a pharmacist. Incremental 
costs, PIPs, and quality adjusted life years (QALYs) at 12 months follow up were estimated 
using multilevel regression. Uncertainty was explored using cost effectiveness acceptability 
curves.  
 
Results:  
The intervention was associated with a non-significant mean cost increase of €407 (95% CIs: 
-357, 1170), a significant mean reduction in PIPs of 0.379 (95% CI: 0.092, 0.666), and a non-
significant mean increase in QALYs of 0.013 (95% CIs: -0.016, 0.042). The incremental cost 
per PIP avoided was €1,269 (95% CI: -1400, 6302) and the incremental cost per QALY gained 
was €30,535 (95% CI: -334,846, 289,498). The probability of the intervention being cost 
effective was 0.602 at a threshold value of €45,000 per QALY gained and was at least 0.845 at 
threshold values of €2,500 per PIP avoided and higher. 
 
Conclusions:  
While the OPTI-SCRIPT intervention was effective in reducing potentially inappropriate 
prescribing in primary care in Ireland, our findings highlight the uncertainty with respect to its 
cost effectiveness. Further studies are required to explore the health and economic implications 
of interventions targeting potentially inappropriate prescribing. 
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INTRODUCTION  
 
Potentially inappropriate prescribing describes suboptimal prescribing practices that increase 
the risk of adverse drug events for patients in circumstances where safer, more effective 
treatment alternatives are available for the condition of interest (1). Within the overall patient 
population, older people, with their relatively high prevalence of multimorbidity and 
consequent polypharmacy, are particularly vulnerable to potentially inappropriate prescribing 
and pose particularly challenging prescribing decisions for healthcare providers (2). A number 
of published tools to assess potentially inappropriate prescribing in older people exist, the 
majority of which are explicit: for example, by listing drugs that should to be avoided (1). 
Applying these tools, potentially inappropriate prescribing in older people has been found to 
be common across healthcare settings and can result in increased morbidity, adverse drug 
events (ADEs), hospitalisations (2,3) and healthcare costs (4). In the Irish healthcare setting, 
potentially inappropriate prescribing in community-dwelling older Irish people has been shown 
to be associated with increased ADEs, accident and emergency (A&E) visits, and poorer health 
related quality of life (5). Moreover, a recent study estimated that 36% of those aged 70 years 
and over had at least one potentially inappropriate prescription (PIP), resulting in additional 
healthcare expenditures of €45 million, or 9% of overall pharmaceutical expenditures for those 
aged 70 years and over in Ireland (4).  
 
Within this context, the development of healthcare interventions which target reductions in 
potentially inappropriate prescribing represent an important public health measure, both in 
terms of their ability to improve patient health outcomes and to reduce the economic burden 
on healthcare systems. Such interventions are particularly relevant in primary care where the 
majority of prescribing of medications takes place. There is currently no single interventional 
strategy that has proved to be most effective, but there is an argument that a multifaceted 
approach, which combines a number of techniques within a single intervention, may be likely 
to be more effective (6,7). To date, a limited number of multifaceted interventions targeting 
inappropriate prescribing reductions have been evaluated in primary care and report positive 
findings (8-10). Nonetheless, further evidence on clinical and cost effectiveness is required 
before widespread adoption in primary care can be recommended.  
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The OPTI-SCRIPT (Optimizing Prescribing for Older People in Primary Care: A Cluster 
Randomised Controlled Trial) study sought to explore these questions for the primary care 
setting in Ireland (10-13). To this end, a cluster randomized controlled trial (RCT) was 
conducted to evaluate a multifaceted intervention, incorporating academic detailing with a 
pharmacist and medicines’ review with web-based pharmaceutical treatment algorithms, to 
reduce potentially inappropriate prescribing among older people (10-13). In the clinical 
effectiveness analysis the results indicated that, relative to usual care, the intervention was 
associated with a significant reduction in PIPs overall, largely driven by modifications to the 
prescribing of proton pump inhibitors (10, 13). In addition to clinical effectiveness, any 
decision regarding the adoption of healthcare interventions in clinical practice should depend 
upon their expected cost effectiveness (14). The techniques of economic evaluation are 
concerned with the estimation of such evidence and in this study, we report the results of the 
economic evaluation conducted to examine the cost effectiveness of the OPTI-SCRIPT 
intervention. 
METHODS 
 
The OPTI-SCRIPT Cluster RCT 
Full details of the study methods, consisting of a cluster RCT with 21 general practices and 
196 patients, are published elsewhere (11,12). The Research Ethics Committee of the Irish 
College of General Practitioners (ICGP) approved the study. General practices from the Health 
Research Board (HRB) Centre for Primary Care Research Network were invited to participate 
by email with a follow-up phone call. Practices were eligible if they had at least 80 patients 
aged ≥ 70 years and were based in Dublin. Consenting practices were instructed to randomly 
select 50 patients aged ≥ 70 years with capacity to provide informed consent. Prescriptions of 
these patients were assigned a study ID and sent to the research team where a research 
pharmacist determined if they had selected PIPs as per the study inclusion criteria.  For the 
purposes of the trial, PIPs were defined according to the criteria in Supplementary Table 1 
(11,12). Eligible patients were sent study information packs by the general practice and those 
wishing to participate returned signed consent forms to the research team. Baseline data were 
collected prior to random allocation, which was conducted by an independent researcher using 
minimisation. It was not possible to blind patients or GPs to allocations; however, the outcome 
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assessor was blinded. Full details on the characteristics of the study participants are presented 
in Supplementary Table 2. 
 
The intervention and control treatment alternatives are outlined in Supplementary Table 3. In 
brief, practices (n=10) and patients (n=97) randomised to the control group received usual care 
in primary care in addition to a one-off simple patient-level PIPs feedback. Practices (n=11) 
and patients (n=99) randomised to the intervention group received a multifaceted intervention, 
involving academic detailing with a pharmacist on how to conduct a GP-led medicines review 
with participating patients; medicines reviews supported by web-based pharmaceutical 
treatment algorithms for GPs which provided evidence-based alternative treatment options to 
PIP drugs; and tailored patient information leaflets. The RCT was conducted between October 
2012 and September 2013. All general practices and 190 (97%) patients were followed up on 
intervention completion at approximately 4 to 6 months and at 12 months at the end of the trial 
follow up. Six patients (3 intervention and 3 control) were lost to follow up, while 35 patients 
(17 intervention and 18 control) did not return the follow up questionnaire.  
Economic Evaluation  
The economic evaluation was conducted following the guidelines for health technology 
assessment for Ireland (15). It consisted of a trial-based analysis with a time horizon of 12 
months; that is, the trial follow up period. The perspective of the healthcare provider was 
adopted with respect to costing and health outcomes were expressed in terms of PIPs and 
Quality Adjusted Life Years (QALYs). Data on resource use, PIPs and health status, 
specifically the Euroqol EQ5D-3L instrument (16) were collected via practice note searches of 
patient charts and patient questionnaires at baseline and at 12 months follow up. Given the 
length of follow up, neither costs nor outcomes were discounted.  
 
The statistical analysis was conducted on an intention to treat basis, and in accordance with 
current guidelines for cluster RCTs (17, 18). That is, we adopted multilevel statistical 
techniques which recognise both the clustering and correlation in the cost and effectiveness 
data. Descriptive statistics were estimated to summarise the variables of interest. The 
incremental analysis was undertaken using generalised estimating equations (GEE), a flexible 
multivariate regression framework that explicitly allows for the modelling of normal and non-
normal distributional forms of clustered data (14). Uncertainty in the analysis was addressed 
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by estimating 95% confidence intervals and cost effectiveness acceptability curves (CEACs), 
which link the probability of cost effectiveness to a range of potential threshold values (λ) that 
health policy makers may be willing to pay per additional unit of health gain (19,20). In 
addition, a series of sensitivity analyses were conducted. All analysis was undertaken in the 
Stata 13 statistical software package [StataCorp College Station, Texas, USA]. 
Cost Analysis 
Three cost components were included in the analysis, all of which were expressed in Euros (€) 
in 2013 prices. Resource use was captured via a combination of practice note searches and 
patient questionnaires, and a vector of unit costs (see Table 1) was applied to calculate the costs 
associated at baseline and follow up. Unit cost estimates for each activity were based on 
national data sources (listed in Table 1) and, where necessary, were transformed to Euros (€) 
in 2013 prices using appropriate indices (15). 
 
The first component related to the cost of implementing the intervention in clinical practice. 
This included a range of resources including the pharmacist and GP time input relating to the 
review and identification of PIPs, educational materials and consumables, and travel expenses. 
Data were recoded prospectively by the study research team and the estimated cost was 
allocated to all patients in the intervention arm (see Table 1 for further details). In sensitivity 
analysis, we explored the implications of increasing the intervention cost per patient by 100%. 
 
Second, the costs relating to PIPs were estimated for the intervention and control groups at 
baseline and at 12 months follow up. Prescriptions for all patients at each time point were sent 
to the research team where a research pharmacist identified PIPs based on the predefined 
criteria specified by the clinical research team. Data on the unit cost per prescription were 
obtained from the primary care reimbursement service (PCRS) for Ireland and applied to 
estimate the cost of PIPs per patient in both treatment arms at baseline and follow up. Notably, 
as data on PIPs referred to the specific data collection point at baseline and follow up, a number 
of assumptions were made to allow for the calculation of the total costs of PIPs over the time 
horizon of the trial of 12 months follow up. For the base-case analysis, it was assumed that the 
PIPs observed at 12 months follow up were applicable to the entire 12 month follow up period. 
In sensitivity analysis, a number of alternative scenarios were explored. First, it was assumed 
that the PIPs observed at baseline were applicable to the first 6 months and that the PIPs 
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observed at follow up were applicable to the final 6 months of follow up. Second, it was 
assumed that the PIPs observed at baseline were applicable to the first 9 months and that the 
PIPs observed at follow up were applicable to the final 3 months of follow up. In addition, to 
reflect a change in pricing policy which came into effect after the trial was completed, we 
conducted a sensitivity analysis to explore the impact of reducing the costs of medications by 
50%. Finally, to address a concern that including the cost of PIPs in the numerator and the 
number of PIPs in the denominator may represent double counting in the incremental cost per 
PIP avoided analysis, we present an analysis with the cost of PIPs excluded. 
 
Third, the costs relating to the use of primary and secondary healthcare services for the 12 
months prior to baseline and for the 12 months follow up period were estimated for patients in 
both treatment arms. This included the costs of GP and practice nurse consultations, outpatient 
clinic visits, A&E clinic visits, and hospital day-case and inpatient admissions.  
 
For the incremental cost analysis, a healthcare provider perspective was adopted and the three 
cost components were combined to generate a total cost variable per patient. Estimation of 
incremental costs at follow up was undertaken using a GEE regression model controlling for 
the treatment arm, baseline cost, age, gender, baseline number of PIPs, number of GPs per 
practice, and practice location. To account for the non-normal nature of the cost data, a Gamma 
variance function were adopted and to account for the hierarchical nature of data, an 
exchangeable correlation structure was used (14). In sensitivity analysis, a GEE regression 
model controlling only for the treatment arm was estimated. 
Effectiveness Analysis 
Health outcomes were expressed in terms of PIPs and QALYs. Complete data were available 
with respect to the number of PIPs in both treatment arms at baseline and follow up. Estimation 
of incremental number of PIPs at follow up was undertaken using a GEE regression model, 
assuming a Gaussian variance function, an identity link function and an exchangeable 
correlation structure, and controlling for the treatment arm, age, gender, baseline number of 
PIPs, number of GPs per practice,  practice location, and clustering. In sensitivity analysis, a 
GEE regression model controlling only for the treatment arm was estimated. 
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Health outcomes were also expressed in terms of QALYs gained which were calculated based 
on patient responses at baseline and follow up to the EuroQol EQ5D-3L instrument (16). The 
EQ5D responses were transformed using an algorithm into a single health state index score, 
based on values elicited via the time trade-off approach for the UK population (16). EQ5D 
scores at baseline and 12 months follow up were used to calculate patient-specific QALYs 
gained over 12 months using the area under the curve method (14). Estimation of incremental 
QALYs was undertaken using a GEE regression model, assuming a Gaussian variance 
function, an identity link function and an exchangeable correlation structure, and controlling 
for treatment arm, baseline EQ5D score, age, gender, baseline number of PIPs, number of GPs 
per practice, practice location, and clustering. In sensitivity analysis, a GEE regression model 
controlling for the treatment arm only was estimated. 
  
Notably, missing data proved to be an issue with respect to the EQ5D data and the resultant 
QALYs estimates. At baseline, data availability was 46% for the intervention and 65% for the 
control. At follow up, these values were 41% and 65%, respectively. As there was no clear 
evidence of systematic bias with respect to the missing data, in sensitivity analysis, multiple 
imputation was undertaken to estimate missing values for EQ5D data to explore the 
implications for the incremental QALYs results. The imputation models for EQ5D data 
included age, gender, practice, and treatment arm (at follow up only) and were estimated using 
predictive mean matching, based on M=5 imputed data sets. The analysis was undertaken using 
the MI estimate mixed and MI predict commands in Stata 13, which estimate the regression 
model on each of the imputed data sets and apply Rubin’s rules to generate the coefficients of 
interest (21) .  
Cost Effectiveness Analysis 
To undertake economic evaluation alongside cluster RCTs, techniques which recognise the 
clustering and correlation in the cost and effectiveness data must be adopted (18, 20). Separate 
multilevel regression models, controlling for treatment arm, clustering, and a range of other 
covariates, were used to estimate the incremental costs, PIPs and QALYs for the intervention 
relative to the control. The uncertainty surrounding these point estimates was examined using 
CEACs, which report the probability of an intervention being cost effective, relative to a 
comparator, for a range of potential threshold values per unit of health gain (19). In the Irish 
context, it is recommended that results be presented for cost effectiveness thresholds of up to 
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€45,000 per QALY gained (15). As no such recommendation exist for potentially inappropriate 
prescribing related outcomes, results are presented for a range of values up to €4,500 per PIP 
avoided. Notably, we explicitly assume that the threshold values adopted, which are typically 
assumed to apply over a lifetime time horizon, are applicable to the 12 month time horizon of 
our evaluation.  
RESULTS 
 
Descriptive statistics for resource use, costs and health outcomes at baseline and follow up are 
presented in Table 2. The total cost of implementing the intervention was €5,824 giving a mean 
cost per patient estimate of €58. Summary data for the proportion of patients with each category 
of PIP at baseline and follow up are reported in Table 3. Notably, prescriptions of proton pump 
inhibitors constituted the largest single class of PIP identified in the intervention and control 
arms at baseline and follow up.  
 
The results from the incremental analyses are presented in Table 4. In terms of total costs at 12 
months follow up, the estimated mean cost per patient was €3075 (95% Confidence Interval 
(CI): 2704, 3446) for the intervention group and €2668 (95% CI: 2297, 3040) for the control 
group. The intervention was associated, on average, with an increase in cost of €407 (95% CIs: 
-357, 1170) per patient compared to the control.  
 
With respect to health outcomes, the mean number of PIPs at 12 months follow up was 
estimated at 0.627 (95% CI: 0.588, 0.666) for the intervention group and 1.006 (95% CI: 0.967, 
1.045) for the control group. The intervention was associated with a mean reduction of 0.379 
(95% CI: -0.666, -0.092) PIPs relative to the control. Mean QALYs gained per patient at 12 
months was estimated to be 0.671 (95% CI: 0.625, 0.716) in the intervention group and 0.657 
(95% CI: 0.612, 0.703) in the control group. The intervention was associated, on average, with 
an increase of 0.013 (95% CIs: -0.016, 0.042) in QALYs gained. 
 
These estimates translated into incremental cost effectiveness ratios (ICERs) of €30,535 (95% 
CI: -334846, 289498) per QALY gained and €1,269 (95% CI: -1400, 6302) per PIP avoided. 
The probabilistic results are summarised in Table 4 and Supplementary Figures 1 and 2 and 
indicate that the probability of the intervention being cost effective was at least 0.845 at 
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threshold values of €2,500 per PIP avoided and higher. Notably, the probability of the 
intervention being cost effective was only 0.602 at a threshold value of €45,000 per QALY 
gained. 
 
The results from the sensitivity analyses are presented in Supplementary Tables 4-10. These 
broadly reflect the results from the base-case analysis, with the intervention consistently 
estimated to be more costly and more effective than the control. Notably, the imputed cost 
utility analysis reported higher estimates for the probability of the intervention being cost 
effective relative to the control. Additional results from univariate analysis of resource costs 
are presented in Supplementary Table 11 and indicate that only the costs of PIPs differed 
significantly across treatment arms at follow up. 
 
DISCUSSION 
 
This study examined the cost effectiveness of the OPTI-SCRIPT intervention, which has been 
shown to be effective in reducing potentially inappropriate prescribing relative to usual primary 
care in Ireland (10-13). The results indicate that, on average, the intervention was more costly 
and more effective, in terms of PIPs avoided and QALYs gained, compared to the control. 
Notably however, while there was evidence of a statistically significant reduction in PIPs, there 
was no such evidence for the difference in mean costs or the difference in mean QALYs. That 
is, the observed reduction in PIPs did not translate into statistically significant improvements 
in QALYs or statistically significant reductions in healthcare costs. Indeed, this finding reflects 
the ambiguity that exists in the literature with respect to the longer term implications of PIPs. 
For example, recent prospective cohort studies have reported that PIPs were associated with 
increased healthcare utilisation, increased ADEs and diminished quality of life (22, 23); 
whereas other studies have reported the magnitude of these effects to be modest (2,3,4). 
 
This raises the question of whether the lack of evidence with respect to QALYs reflects an 
absence of a clinically significant treatment effect or whether it reflects a lack of sensitivity in 
the EQ5D instrument, or indeed how we have employed it in our analysis, to detect a clinically 
meaningful improvement in health status for the older patient population under consideration. 
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It may also be the case that our analysis, which was limited to a time horizon of the 12 months, 
was too short to capture the longer terms implications of reducing PIPs. Indeed, a common 
criticism of the evaluation literature for prescribing interventions is that sample sizes may be 
too small and follow-up periods too short to detect differences in patient reported outcomes 
(24). Finally, a further explanation may be that our findings related mainly to proton pump 
inhibitor prescriptions and reductions in such prescriptions may not significantly impact upon 
self-rated health status.  
 
Our results also indicated that the reduction in PIPs did not lead to a statistically significant 
difference in mean healthcare costs between the intervention and the control. Indeed, and 
although not statistically significant, when intervention costs, PIP costs, and other healthcare 
service costs over the 12 month follow up period were combined, the intervention was, on 
average, more costly than the control. That said, there was no evidence of statistically 
significant differences in the costs of individual primary or secondary care services between 
the intervention and control over the course of the trial.  
 
These issues notwithstanding, in circumstances where an intervention is, on average, more 
costly and more effective than a control comparator, it will only be judged cost effective if its 
ICER falls below the threshold value that policy makers would be willing to pay for an 
additional unit of health gain (14). The ICER from the cost utility analysis of €30,535 per 
QALY gained is likely to be viewed favourably in the Irish context, and in other similar 
jurisdictions, where a threshold value in the region of €45,000 per QALY has been proposed 
(15). Nonetheless, the uncertainty surrounding this ICER point estimate must be also taken into 
account. In this case, the probabilistic results indicate the likelihood of the intervention being 
cost effective to be 0.602 at a threshold value of €45,000 per QALY. Such a level of uncertainty 
is unlikely to be deemed sufficient to justify adoption in clinical practice. Notably, the response 
rate to the EQ5D questionnaire had a direct impact of this finding as this probability estimate 
increased to 0.764 when the missing EQ5D score data was imputed and the cost utility analysis 
was re-estimated.  
 
The results from the cost effectiveness analysis provide additional evidence. Importantly, while 
there is no formal threshold value per PIP avoided for Ireland or elsewhere, we present results 
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for a set of potential threshold values for illustrative purposes. The robust findings for the 
statistically significant reduction in PIPs associated with the intervention are reflected in the 
cost effectiveness probability estimates, which increase as the threshold value per PIP avoided 
increases. For example, if decision makers were willing to pay at least €2,500 to avoid a PIP, 
there is a probability of 0.845 or higher of the intervention being cost effective. That said, 
whether or not this proves to be an appropriate range of threshold values in this context is open 
to debate. Taken together, the ultimate determination of the cost effectiveness of the OPTI-
SCRIPT intervention will depend on the relevant policy maker’s threshold value per PIP 
avoided and QALY gained, as well as their attitude towards uncertainty. 
 
This study adds to the limited literature of interventions targeting reductions in potentially 
inappropriate prescribing in primary care. Of those interventions that have been evaluated, 
single interventions such as computerised decision support systems (CDSSs), educational 
interventions, and multidisciplinary teams have produced inconsistent effects (2, 24, 25) . More 
recently, two separate RCTs have found that multifaceted interventions are effective (8,9). 
Rognstad et al (9) found that peer academic detailing, delivered at continuing medical 
education (CME) meetings, with mailed prescriber feedback, produced a 10% (95% CI 5.9 to 
15.0) reduction in PIP. Similarly, Bregnhoj et al (8) found that interactive educational meetings 
and feedback resulted in a 5 point (95% CI: 2.6 to 7.3) improvement in the medication 
appropriateness index (MAI) score. Differences in effect sizes reported between these studies 
and the OPTI-SCRIPT findings may arise from a number of factors including differences in 
the criteria used to assess PIPs, the duration of follow-up and the patients included and the 
context of care (10,13). 
 
The study was subject to a number of limitations. First, the limitations associated with the RCT 
(11,12) on which the analysis was based are also applicable to the economic evaluation. There 
were a number of issues with respect to the cost analysis. In the case of costing PIPs, given 
data issues, we made the explicit assumption that all PIPs represented inappropriate cases and 
there were no cases in which a PIP would have been substituted for an alternative medication. 
In addition, we made a series of assumptions to cost PIPs over the 12 month trial follow up 
period. Furthermore, while the cost analysis was conducted from the healthcare service 
perspective and included a broad range of resource use activities, certain resource items were 
not captured. For example, the costs of community care services, private patient costs such as 
private health insurance premiums, and broader costs to society such as productivity losses 
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were not captured. Nonetheless, there is little evidence to suggest that the inclusion of such 
resource categories would have significantly changed the results. Finally, the process of 
conducting cost analysis in Ireland is compromised by the lack of nationally available unit cost 
data. In estimating unit costs for individual resource activities, we endeavoured at all times to 
be conservative in any assumptions adopted. It should also be noted that we adopt 2013 prices 
for the analysis and medical inflation has fallen in the period since the trial was conducted. To 
examine the uncertainty surrounding the cost analysis, a series of sensitivity analysis were 
conducted, the results from which did not differ fundamentally from those of the base-case 
analysis. 
 
There were also a number of limitations in relation to the health outcome analysis. In particular, 
the available PIP data only reflected medications that were prescribed and did not capture 
whether or not the medication was subsequently dispensed and taken by the patient. With 
respect to the estimation of QALYs, given the lack of Irish utility data for the EQ5D-3L 
instrument, the equivalent UK algorithm was adopted and assumed to be generalisable to the 
older Irish population. Furthermore, the patient response rate for the EQ5D-3L questionnaire 
was disappointing and was reflected in the cost utility analysis results. In sensitivity analysis, 
after careful consideration of missing data patterns, we proceeded with the assumption that the 
data were missing at random and multiple imputation was undertaken to impute missing values. 
The imputation process adopted is subject to criticism as the variables included in the 
imputation models were pragmatically chosen by the study team and the values for costs and 
EQ5D scores were imputed independently (18). Nonetheless, the imputed results provide 
useful additional information on the potential cost effectiveness of the intervention. 
 
Finally, in the case of chronic disease, a lifetime time horizon for analysis is encouraged as 
interventions may have long term implications which occur beyond the end of trial follow up 
(14). Additional follow up of the trial sample should be conducted to explore the longer term 
implications of the results presented here. 
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CONCLUSION 
 
This study presents cost effectiveness evidence for the OPTI-SCRIPT intervention in reducing 
potentially inappropriate prescribing in primary care in Ireland. While we report that the OPTI-
SCRIPT intervention was effective in reducing PIPs, uncertainty exists with respect to its cost 
effectiveness.There was strong evidence that the intervention was cost-effective if decision 
makers were willing to pay at least €1,269 per PIP avoided; however the evidence was much 
less compelling when effectiveness was measured in terms of QALYs gained. Further studies 
are required to explore the longer term health and economic implications of interventions 
targeting potentially inappropriate prescribing in primary care. 
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Table 1 – Categories of resource use and unit cost estimates in 2013 (€) prices 
 
Resource item  
 
Activity Unit cost 
€ 
Source 
OPTI-SCRIPT intervention 
General Practitioner( GP) review consultation 
Pharmacist Academic Detailing 
Travel Expenses 
Materials and Consumables 
 
Healthcare resources   
General Practitioner(GP) Visits 
Practice Nurse Visits 
Outpatient Clinic Visits 
Day Case Admission 
Inpatient Admission 
Accident and Emergency (A&E) Visits  
 
Potentially inappropriate prescriptions 
Proton Pump Inhibitor  (PPI ) 
Nonsteroidal anti-inflammatory drug (NSAID) 
Long-term benzodiazepines (Long acting benzo) 
Short-acting benzodiazepines( BenzoSA) 
Tricyclic Anti-depressant (TCA) 
Aspirin 
Theophylline 
Antihistamine 
Bladder antimuscarinic drugs (BA) 
Digoxin 
Thiazide diuretic (TD) 
Glibenclamide 
Prochlorperazine or metoclopramide (P/M)  
Calcium channel blockers (CCB) 
Long-term corticosteroids (LT_ steroid) 
Chronic obstructive pulmonary disease (COPD) steroid 
Osteoarthritis (OA) steroid 
 
Per Patient 
Per Patient 
Per Patient 
Per Patient 
 
 
Per Consultation 
Per Consultation 
Per Consultation 
Per Day 
Per Night 
Per Consultation 
 
 
Per Pack  
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
Per Pack 
 
50 
4 
1.50 
2.50 
 
 
50 
12 
142 
671 
777 
270 
 
 
EUR 6.90 - EUR 13.72 
 EUR5.04 -  EUR89.39 
EUR 1.10- EUR 8.07 
EUR 2.12 – EUR 19.15 
EUR 3.70- EUR 14.80 
EUR 1.03- EUR 36.5 
EUR 2.30 – EUR 8.35 
EUR 1.91 
EUR 20.69- EUR 34.26 
EUR 8.48- EUR 9.04 
EUR 2.34- EUR 33.59 
EUR 6.20 
EUR 4.35-EUR11.98 
 EUR 5.85- EUR9.46 
EUR 6.21- EUR 19.09 
EUR 6.40- EUR 21.60 
EUR 6.40- EUR 21.60 
 
Study Accounts 
Study Accounts 
Study Accounts 
Study Accounts 
 
 
ORC 
ORC 
DOHC 
DOHC 
DOHC 
DOHC 
 
 
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
PCRS  
 
ORC – Office of the Revenue Commissioner, Dublin, Ireland. 
DOHC – Casemix Unit, Department of Health and Children, Dublin, Ireland 
PCRS - Primary Care Reimbursement Service, Health Service Executive, Dublin, Ireland 
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Table 2 – Resource Use, costs and health outcomes at baseline and 12 months follow up  
 
 Intervention (N=99) 
Mean (SD)  
Control (N=97) 
Mean (SD)  
Resource item Usage Cost (€) Usage Cost (€) 
Baseline potentially inappropriate prescriptions*  
Number of PIP at Baseline  
 
Baseline healthcare resource use 
GP Visits 
GP Visits: Script Only† 
Practice Nurse Visits 
Out of Hours GP Visits 
Outpatient Visits 
Day Case Admission 
Inpatient Admission 
A&E Visits 
 
1.31 (0.6) 
 
 
8.7 (4.1) 
2.9 (3.6) 
1.8 (2.7) 
0.2 (0.7) 
2.5 (2.5) 
0.1 (0.3) 
0.9 (3.5) 
0.1 (0.4) 
 
230 (172) 
 
 
434 (203) 
143 (180) 
21 (32) 
10 (36) 
355 (351) 
49 (175) 
688 (2705) 
34 (113) 
 
1.39 (0.6) 
 
 
8.7 (5.2) 
2.5 (3.0) 
1.5 (1.8) 
0.2 (0.7) 
2.3 (2.3) 
0.1 (0.4) 
0.9 (3.2) 
0.1 (0.3) 
 
302 (186) 
 
 
432 (260) 
123 (151) 
19 (22) 
10 (34) 
327 (327) 
79 (239) 
660 (2489) 
26 (80) 
Follow up potentially inappropriate prescriptions* 
Number of PIP at Follow Up 
 
Follow up healthcare resource use 
GP Visits 
GP Visits: Script Only† 
Practice Nurse Visits 
Out of Hours GP Visits 
Outpatient Visits 
Day Case Admission 
Inpatient Admission 
A&E Visits 
 
OPTI-SCRIPT Intervention 
 
0.61 (0.7) 
 
 
8.0 (4.5) 
2.2 (2.6) 
2.0 (2.6) 
0.2 (0.5) 
2.4 (2.0) 
0.2 (0.5) 
1.9 (5.7) 
0.2 (0.4) 
 
99 (100%) 
 
93 (131) 
 
 
398 (225) 
112 (131) 
24 (31) 
7 (24) 
343 (277) 
119 (364) 
1497 (4430) 
39 (117) 
 
58 (na) 
 
1.03 (0.8) 
 
 
8.1 (4.8) 
2.2 (2.6) 
1.6 (2.4) 
0.1 (0.4) 
2.4 (2.2) 
0.2 (0.5) 
1.6 (5.2) 
0.1 (0.4) 
 
0(0%) 
 
200 (217) 
 
 
405 (242) 
110 (128) 
19 (29) 
7 (19) 
342 (314) 
101 (312) 
1270 (4001) 
38 (117) 
 
0 (na) 
Health outcome Intervention (N=99) 
Mean (SD)  
Control (N=97) 
Mean (SD)  
EQ5D Score at baseline 
EQ5D Score at follow up 
0.628 (0.302) 
0.665 (0.268) 
0.689 (0.236) 
0.652 (0.248) 
 
Completeness of data at baseline: Intervention – 96/99 (97%) for primary and secondary care utilisation, 99/99 (100%) for 
PIPs, 45/99 (46%) for EQ5D. Control: 93/97 (96%) for primary and secondary care utilisation, 97/97 (100%) for PIPs, 63/97 
(65%) for EQ5D. 
 
Completeness of data at follow up: Intervention – 96/99 (97%) for primary and secondary care utilisation, 99/99 (100%) 
for PIPs, 41/99 (41%) for EQ5D, 37/99 (37%) for QALY and 95/99 (96%) for Total Cost. Control: 93/97 (96%) for primary 
and secondary care utilisation, 97/97 (100%) for PIPs, 63/97 (65%) for EQ5D, 54/97 (56%) for QALY and 93/97 (96%) for 
Total Cost. 
 
* Potentially inappropriate prescriptions are medicines whose potential harms may outweigh their benefits. The PIPs 
inclusion criteria are described in Supplementary Table 1. Patient repeat medications were reviewed by a research 
pharmacist to confirm if patients had PIP as per this list. 
 
† For repeat prescriptions, GPs may pre authorise for patients to have a script issued, without having a GP consultation.  
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Table 3 – Potentially inappropriate prescriptions at baseline and 12 months follow up 
 
Potentially inappropriate prescriptions (PIP)* Intervention (N=99) 
% 
Control (N=97) 
% 
 Baseline Follow Up Baseline Follow Up 
Proton pump inhibitor  (PPI ) 
Nonsteroidal anti-inflammatory drug (NSAID) 
Long-term benzodiazepines (Long acting benzo) 
Short-acting benzodiazepines(BenzoSA) 
Tricyclic Anti-depressant (TCA) 
Aspirin 
Theophylline 
Antihistamine 
Bladder antimuscarinic drugs (BA) 
Digoxin 
Thiazide diuretic (TD) 
Glibenclamide 
Prochlorperazine or metoclopramide (P/M)  
Calcium channel blockers (CCB) 
Long-term corticosteroids (LT_ steroid) 
Chronic obstructive pulmonary disease (COPD) steroid 
Osteoarthritis (OA) steroid 
Therapeutic Duplication 
53% 
21% 
14% 
0% 
1% 
3% 
0% 
4% 
1% 
1% 
3% 
0% 
0% 
0% 
0% 
0% 
9% 
19% 
26% 
3% 
8% 
0% 
1% 
5% 
0% 
1% 
2% 
0% 
1% 
0% 
0% 
2% 
0% 
0% 
3% 
3% 
68% 
17% 
8% 
0% 
5% 
1% 
0% 
2% 
9% 
3% 
2% 
0% 
0% 
3% 
0% 
0% 
4% 
14% 
43% 
8% 
9% 
0% 
3% 
2% 
0% 
2% 
6% 
3% 
2% 
0% 
0% 
2% 
1% 
0% 
2% 
9% 
 
 
* Potentially inappropriate prescriptions are medicines whose potential harms may outweigh their benefits. The PIPs 
inclusion criteria are described in Supplementary Table 1. Patient repeat medications were reviewed by a research 
pharmacist to confirm if patients had PIP as per this list. 
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Table 4 – Incremental cost effectiveness analysis and cost utility analysis results 
 
 INCREMENTAL ANALYSIS  
(Intervention versus Control) 
Cost Analysis Intervention Control 
Healthcare Costs 
(95% CIs) 
3075 
(2704, 3446) 
2668 
(2297,  3040) 
Difference in Healthcare Cost  
(95% CIs) 
407 
 (-357, 1170) 
 INCREMENTAL ANALYSIS  
(Intervention versus Control) 
Effectiveness Analysis Intervention Control 
Number of PIPs 
(95% CIs) 
0.627 
(0.588,  0.666) 
1.006 
(0.967,  1.045) 
Difference in Number of PIPs  
(95% CI) 
-0.379 
 (-0.666, -0.092) 
 INCREMENTAL ANALYSIS  
(Intervention versus Control) 
Effectiveness Analysis Intervention Control 
QALYs  
(95% CIs) 
0.671 
(0.625, 0.716) 
0.657 
 (0.612, 0.703) 
Difference in QALYs (95% CI) 0.013 
(-0.016, 0.042)   
 INCREMENTAL ANALYSIS  
(Intervention versus Control) 
ICER per PIP avoided (€) 
(95% CIs) 
1269 
(-1400, 6302) 
ICER per QALYs gained (€) 
(95% CIs) 
30535  
(-334846, 289498) 
Probability that the Intervention is Cost 
Effective PIP Avoided QALY Gained 
 Threshold Value (λ) P [CE] 
Threshold 
Value (λ) P [CE] 
 λ = €0 0.143 λ = €0 0.138 
 λ = €500 0.278 λ = €5,000 0.184 
 λ = €1,500 0.654 λ = €15,000 0.315 
 λ = €2,500 0.845 λ = €25,000 0.454 
 λ = €3,500 0.926 λ = €35,000 0.534 
 λ = €4,500 0.951 λ = €45,000 0.602 
 
Completeness of Data: Intervention –99/99 (100%) for PIPs, 37/99 (37%) for QALY and 95/99 (96%) for 
Total Cost. Control: 97/97 (100%) for PIPs, 54/97 (56%) for QALY and 93/97 (96%) for Total Cost. 
 
Incremental Cost Analysis: Estimated by a generalised estimating equation regression model, assuming a 
Gamma variance function, an identity link function and an exchangeable correlation structure, controlling for 
treatment arm, age, gender, baseline number of PIP drugs, baseline cost, number of GPs and practice location. 
 
Incremental PIP Analysis: Estimated by a generalised estimating equation regression model, assuming a 
Gaussian variance function, an identity link function and an exchangeable correlation structure, controlling for 
treatment arm, age, gender, baseline number of PIP drugs, number of GPs and practice location. 
 
Incremental QALY Analysis: Estimated by a generalised estimating equation regression model, assuming a 
Gaussian variance function, an identity link function and an exchangeable correlation structure, controlling for 
treatment arm, age, gender, baseline number of PIP drugs, baseline eq5d score, number of GPs and practice 
location. 
 
